Imugene Limited (ASX:IMU) has been granted a trading halt by the ASX with an announcement pending in relation to a proposed capital raising.
The trading halt will remain in place until the beginning of normal trading on Monday, December 2, 2019, or when an announcement is released to the market, whichever occurs earliest.
Imugene's securities last traded at 4.4 cents after reaching a new 12-month high of 6.3 cents on November 22.
Two separate phase-I clinical trials
Earlier this month the company recently revealed plans to conduct two separate phase-I clinical trials in 2020 to test two constructs of the CF 33 oncolytic virus (OV).
One version of the OV is “armed” with an immune checkpoint inhibitor inserted in the virus, which is known as CheckVacc.
The second is an unarmed construct known as Vaxinia.
Both constructs have completed clinical-grade GMP batches at the City of Hope Cenrtre for Biomedicne and Genetics (CBG).